| Literature DB >> 26783840 |
Tetsuji Azuma1, Mayu Yamane2, Daisuke Ekuni3, Yuya Kawabata4, Kota Kataoka5, Kenta Kasuyama5, Takayuki Maruyama6, Takaaki Tomofuji7, Manabu Morita8.
Abstract
Oxidative stress is involved in the pathogenesis of periodontitis. A reduction of oxidative stress by drinking hydrogen-rich water (HW) might be beneficial to periodontal health. In this pilot study, we compared the effects of non-surgical periodontal treatment with or without drinking HW on periodontitis. Thirteen patients (3 women, 10 men) with periodontitis were divided into two groups: The control group (n = 6) or the HW group (n = 7). In the HW group, participants consumed HW 4-5 times/day for eight weeks. At two to four weeks, all participants received non-surgical periodontal treatment. Oral examinations were performed at baseline, two, four and eight weeks, and serum was obtained at these time points to evaluate oxidative stress. At baseline, there were no significant differences in periodontal status between the control and HW groups. The HW group showed greater improvements in probing pocket depth and clinical attachment level than the control group at two, four and eight weeks (p < 0.05). The HW group also exhibited an increased serum level of total antioxidant capacity at four weeks, compared to baseline (p < 0.05). Drinking HW enhanced the effects of non-surgical periodontal treatment, thus improving periodontitis.Entities:
Keywords: drinking water; hydrogen; oxidative stress; periodontitis
Year: 2015 PMID: 26783840 PMCID: PMC4665424 DOI: 10.3390/antiox4030513
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Clinical and serum parameters at baseline.
| Parameters | Control Group ( | HW Group ( |
|---|---|---|
| Gender (male) * | 3 (50.0) | 7 (100.0) ‡ |
| Age (years) † | 23 (22, 23.25) | 26 (23, 30) § |
| BMI † | 20.3 (19.0, 22.8) | 21.7 (19.5, 24.8) |
| Periodontal conditions † | ||
| PPD (mm) | 1.87 (1.68, 2.04) | 2.20 (1.69, 2.27) |
| CAL (mm) | 1.87 (1.68, 2.04) | 2.21 (1.69, 2.27) |
| BOP (%) | 11.1 (5.4, 30.4) | 20.8 (8.3, 38.7) |
| PI | 0.2 (0.1, 0.4) | 0.2 (0.1, 1.3) |
| Serum oxidative stress † | ||
| ROM (CARR U) | 294 (248, 371) | 318 (270, 377) |
| OXY (µmol/mL) | 398 (363, 418) | 431 (379, 448) |
* n [%]; † median [25%, 75%]; ‡ p < 0.05, compared with the control group, Fisher’s exact test. § p < 0.05, compared with the control group, Mann-Whitney U test. BMI, Body Mass Index; PPD, probing pocket depth; CAL, clinical attachment level; BOP, bleeding on probing; PI, plaque levels; ROM, reactive oxygen metabolites; OXY, OXY-adsorbent test; HW, hydrogen-rich water.
Changes in clinical parameters at week 2, 4 and 8 (median (25%, 75%)).
| Parameters | Control Group ( | HW Group ( |
|---|---|---|
| PPD (mm) | ||
| Week 2 | 0.12 (0.08, 0.20) * | −0.10 (−0.31, −0.01) ‡ |
| Week 4 | 0.12 (0.07, 0.18) | −0.28 (−0.49, −0.02) †,‡ |
| Week 8 | 0.01 (−0.05, 0.14) | −0.34 (−0.52, −0.11) †,‡ |
| CAL (mm) | ||
| Week 2 | 0.12 (0.08, 0.20) | −0.10 (−0.31, −0.01) ‡ |
| Week 4 | 0.12 (0.07, 0.18) | −0.28 (−0.49, −0.02) †,‡ |
| Week 8 | 0.01 (−0.05, 0.14) | −0.34 (−0.52, −0.11) †,‡ |
| BOP (%) | ||
| Week 2 | 0.00 (−5.06, 5.08) | −2.39 (−13.01, 2.38) |
| Week 4 | 1.79 (−14.14, 3.89) | −11.90 (−24.31, 2.38) † |
| Week 8 | 0.01 (−15.18, 2.67) | −5.96 (−24.41, −0.60) † |
| PI | ||
| Week 2 | 0.00 (−0.04, 0.07) | 0.07 (−0.13, 0.46) |
| Week 4 | −0.02 (−0.19, 0.25) | −0.17 (−0.65, 0.00) † |
| Week 8 | 0.09 (−0.07, 0.13) | −0.03 (−0.72, 0.25) |
* Differences (each time point minus baseline); † p < 0.05, compared with the baseline, using Wilcoxon signed-rank test. ‡ p < 0.05, compared with the control group, using Mann-Whitney U test.
Changes in CAL in each individual (mm).
| Patient | Gender | Age (Years) | Baseline | Week 2 | Week 4 | Week 8 |
|---|---|---|---|---|---|---|
| Control group | ||||||
| A | Male | 22 | 1.78 | 1.90 | 1.93 | 1.79 |
| B | Male | 23 | 1.95 | 2.04 | 2.02 | 1.96 |
| C | Male | 24 | 2.09 | 2.15 | 2.18 | 2.04 |
| D | Female | 22 | 1.73 | 2.01 | 1.89 | 1.68 |
| E | Female | 23 | 1.54 | 1.66 | 1.79 | 1.70 |
| F | Female | 23 | 2.02 | 2.19 | 2.08 | 2.15 |
| HW group | ||||||
| G | Male | 40 | 2.21 | 2.17 | 1.72 | 1.77 |
| H | Male | 30 | 2.27 | 2.17 | 1.99 | 1.93 |
| I | Male | 26 | 2.22 | 1.81 | 1.57 | 1.49 |
| J | Male | 25 | 1.64 | 1.47 | 1.42 | 1.46 |
| K | Male | 28 | 2.32 | 2.01 | 1.84 | 1.80 |
| L | Male | 23 | 1.79 | 1.78 | 1.77 | 1.68 |
| M | Male | 23 | 1.69 | 1.68 | 1.68 | 1.67 |
Changes in biochemical parameters at week 2, 4 and 8 (median (25%, 75%)).
| Parameters | Control Group ( | HW Group ( |
|---|---|---|
| ROM (CARR U) | ||
| Week 2 | 39 (5, 76) * | 35 (3, 42) |
| Week 4 | 49 (29, 85) | 32 (11, 43) |
| Week 8 | 28 (11, 106) † | −15 (−67, 13) ‡ |
| OXY (µmol/mL) | ||
| Week 2 | 24 (11, 67) | −1 (−22, 66) |
| Week 4 | 49 (18, 70) | 56 (−18, 86) † |
| Week 8 | 12 (−46, 35) | 15 (−43, 76) |
* Differences (each time point minus baseline); † p < 0.05, compared with the baseline, using Wilcoxon signed-rank test. ‡ p < 0.05, compared with the control group, using Mann-Whitney U test.